Detection and quantification of mutations in the plasma of patients with colorectal tumors
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients and to develop methods that are sufficiently sensitive to detect these mutations. Using a modified version of a recently developed assay for this purpose, we found that patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli ( APC ) DNA molecules in their plasma. The median number of APC DNA fragments in such patients was 47,800 per ml of plasma, of which 8% were mutant. Mutant APC molecules were also detected in >60% of patients with early, presumably curable colorectal cancers, at levels ranging from 0.01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a crucial consideration when considering cfDNA as a template as its concentration can range considerably; from 2 to 30 ng/ml plasma in healthy individuals to 180–600 ng/ml plasma both during pregnancy and in cancer patients (13,16,18,22–24).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Self-citationJahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., & Knippers, R. (2001) · PubMed · Cited by 2,549
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
(1977) · PubMed · Cited by 1,801
Rapid Clearance of Fetal DNA from Maternal Plasma
Lo, Y. M. D., Zhang, J., Leung, T. N., Lau, T. K., Chang, A. M. Z., & Hjelm, N. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302205 · Cited by 1,157
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
Sidransky, D., Von Eschenbach, A., Tsai, Y. C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S. R., Frost, P., et al. (1991) · Science · doi:10.1126/science.2024123 · Cited by 875
Self-citationDressman, D., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 844
Self-citationIdentification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors
Sidransky, D., Tokino, T., Hamilton, S. R., Kinzler, K. W., Levin, B., Frost, P., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1566048 · Cited by 698
Self-citationEmerging molecular markers of cancer
Sidransky, D. (2002) · Nature Reviews Cancer · doi:10.1038/nrc755 · Cited by 662
American Cancer Society Guidelines for the Early Detection of Cancer, 2006
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.1.11 · Cited by 639
Bias as a threat to the validity of cancer molecular-marker research
Ransohoff, D. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1550 · Cited by 487
Leek, R. D., Landers, R. J., Harris, A. L., & Lewis, C. E. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690158 · Cited by 451
Sozzi, G., Conte, D., Mariani, L., Vullo, S. L., Roz, L., Lombardo, C., Pierotti, M. A., & Tavecchio, L. (2001) · PubMed · Cited by 421
Giacona, M. B., Ruben, G. C., Iczkowski, K. A., Roos, T. B., Porter, D. M., & Sorenson, G. D. (1998) · Pancreas · doi:10.1097/00006676-199807000-00012 · Cited by 387
Molecular Imaging in the Clinical Arena
Jaffer, F. A. (2005) · JAMA · doi:10.1001/jama.293.7.855 · Cited by 369
Choi, J., Reich, C. F., & Pisetsky, D. S. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02130.x · Cited by 198
American Cancer Society Guidelines for the Early Detection of Cancer, 2005
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.31 · Cited by 174
Bernath, K., Hai, M., Mastrobattista, E., Griffiths, A. D., Magdassi, S., & Tawfik, D. S. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2003.10.005 · Cited by 165
Bremnes, R. M., Sirera, R., & Camps, C. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.12.008 · Cited by 135
Stool screening for colorectal cancer: evolution from occult blood to molecular markers
Ahlquist, D. A., & Shuber, A. P. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00712-4 · Cited by 117
Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
Yu, R. Z., Geary, R. S., Monteith, D., Matson, J. E., Truong, L., Fitchett, J. R., & Levin, A. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10473 · Cited by 114
Chen, S., Yu, L., Jiang, C., Zhao, Y., Da Yu, S. U. N., Li, S., Liao, G., Chen, Y., Fu, Q., Tao, Q., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.108 · Cited by 112
Nylander, K., Bourdon, J.-C., Bray, S. E., Gibbs, N. K., Kay, R., Hart, I., & Hall, P. A. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200001)190:1<39::aid-path492>3.0.co;2-v · Cited by 98
New Cancer Biomarkers Deriving from NCI Early Detection Research
Verma, M., & Srivastava, S. (2003) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-55647-0_7 · Cited by 58
Molecular detection of low-level disease in patients with cancer
Burchill, S. A., & Selby, P. J. (2000) · The Journal of Pathology · Cited by 52
Ghadessy, F. J., & Holliger, P. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh025 · Cited by 44
Methylated DNA as a possible screening marker for neoplastic disease in several body fluids
Müller, H. M., & Widschwendter, M. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.4.443 · Cited by 43
TOWARD A SYSTEM OF CANCER SCREENING IN THE UNITED STATES: Trends and Opportunities
Breen, N., & Meissner, H. I. (2004) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.26.021304.144703 · Cited by 41
Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients
Lotze, M. T., Wang, E., Marincola, F. M., Hanna, N., Bugelski, P. J., Burns, C. A., Coukos, G., Damle, N. K., Godfrey, T. E., Howell, W. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000154251.20125.2e · Cited by 32
Diagnostic potential of circulating nucleic acids for oncology
Goessl, C. D. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.4.431 · Cited by 27
Winawer, S. J., Faivre, J., Selby, J. V., Bertaro, L., Chen, T. H.-H., Kroborg, O., Levin, B., Mandel, J., O'Morain, C. A., Richards, M., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdi029 · Cited by 15
Colorectal carcinoma in endoscopic biopsies; additional histologic criteria for the diagnosis
Cerar, A., Zidar, N., & Vodopivec, B. (2004) · Pathology - Research and Practice · doi:10.1016/j.prp.2004.06.010 · Cited by 11
Screening for Cancer: Are Resources Being Used Wisely?
Kaplan, R. M. (2005) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/3-540-26980-0_20 · Cited by 8
Lieberman, D. A., & Atkin, W. S. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.0953-0673.2004.01842.x · Cited by 6
Grimminger, A. (1955) · PubMed · Cited by 3
Research works printed but not linked: 4
- 10.1002/(SICI)1096-9896(200001)190:1<6::AID-PATH486>3.0.CO;2-M · doi:10.1002/(sici)1096-9896(200001)190:1<6::aid-path486>3.0.co;2-m
- Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. (1977) Cancer Res. 37, 646-650.837366
- Sozzi, G., Conte, D., Mariani, L., Lo Vullo, S., Roz, L., Lombardo, C., Pierotti, M. A. & Tavecchio, L. (2001) Cancer Res. 61, 4675-4678.11406535
- Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D. & Knippers, R. (2001) Cancer Res. 61, 1659-1665.11245480
Cited by
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationCell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Self-citation
Metadata
- Authors
- Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-10-28
- Volume
- 102
- Issue
- 45
- Pages
- 16368-16373
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1283450
- OpenAlex
- W2015438948
- Cited by
- 1,188
- References
- 39
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 44 · 2023: 75 · 2022: 91 · 2021: 76 · 2020: 88 · 2019: 111 · 2018: 97 · 2017: 93 · 2016: 90 · 2015: 66 · 2014: 61 · 2013: 46 · 2012: 44
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA62924, CA43460, CA57345)
- National Cancer Institute (CA 57345, CA43460, R37CA043460, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- circulating tumor DNA, colorectal cancer, APC mutation, liquid biopsy, early cancer detection
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Mutation, Sensitivity and Specificity, Colorectal Neoplasms, Genes, APC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.